Report Description Table of Contents How Are CAR-T Treatment Volumes, Solid Tumor Approvals and Next-Generation Cell Therapies Shaping the Novel T-Cell Immunotherapy Market? – (Updated On: 20th-Nov-2026) According to Strategic Market Research, the Global Novel T-Cell Immunotherapy Market was valued at USD 6.35 billion in 2025 and is projected to reach USD 19.50 billion by 2032, growing at a CAGR of 17.1% during 2026–2032. CAR-T therapies remain the primary commercial contributors, supported by approved treatments for leukemia, lymphoma, and multiple myeloma. Meanwhile, FDA approvals of TIL and TCR-T therapies are extending cellular immunotherapy into selected solid tumors, while regulatory T-cell treatments and allogeneic CAR-T programs are creating additional development opportunities in transplantation and autoimmune diseases. The European Society for Blood and Marrow Transplantation (EBMT) recorded 4,757 CAR-T procedures in its registry during 2025, demonstrating established treatment activity across European cellular therapy centers. CAR-T Treatment Adoption and Clinical Demand: Hematological malignancies remain the largest established application for T-cell immunotherapy. The U.S. FDA lists seven approved CAR-T products targeting CD19 and BCMA, covering several forms of leukemia, lymphoma, and multiple myeloma. In December 2025, the FDA approved Bristol Myers Squibb's Breyanzi for eligible patients with relapsed or refractory marginal zone lymphoma, supported by clinical evidence involving 66 treated patients. The expansion of approved indications provides additional treatment opportunities within established CAR-T platforms. Solid Tumor Treatment Expansion: TIL and TCR-T approvals are establishing additional applications beyond blood cancers. The FDA-approved Amtagvi demonstrated an objective response rate of 31.5% among 73 treated patients with previously treated advanced melanoma. Adaptimmune's Tecelra demonstrated a 43.2% response rate among 44 treated patients with eligible synovial sarcoma. These clinical results support the development of tumor-infiltrating lymphocytes and engineered T-cell receptors as distinct treatment approaches for selected solid tumors. Autoimmune Disease Applications: Pharmaceutical development is increasingly examining engineered T cells for severe autoimmune disorders, including systemic sclerosis, systemic lupus erythematosus, and inflammatory myopathies. In November 2026, Allogene Therapeutics reported preliminary Phase 1 results for ALLO-329, with 18 patients treated across three autoimmune indications. Eight of 10 patients with systemic sclerosis achieved and maintained a clinically meaningful improvement in skin-disease scores, while nine remained off background immunosuppressive therapy at the reported assessment. The findings provide early clinical evidence for allogeneic CAR-T development beyond oncology. Regulatory T-Cell Therapy and Transplantation: The U.S. FDA approved Orca Bio's Tregzi on June 30, 2026, for eligible adults undergoing matched-donor hematopoietic stem cell transplantation for hematological malignancies. The supporting Precision-T trial randomized 187 patients and reported one-year chronic graft-versus-host disease-free survival of 78% with Tregzi compared with 38.4% in the control group. This approval establishes a separate clinical application for regulatory T-cell-based treatments in transplantation and immune regulation. Regulatory Changes and Treatment Accessibility: In June 2025, the FDA eliminated Risk Evaluation and Mitigation Strategies (REMS) requirements for approved autologous CD19- and BCMA-directed CAR-T therapies, removing special hospital certification and mandatory immediate on-site access to tocilizumab under these programs. The agency indicated that the change could improve treatment access, particularly for patients living in rural areas, while retaining product labeling and routine safety monitoring requirements. This regulatory development reduces certain administrative barriers for hospitals offering CAR-T treatment. Allogeneic and Next-Generation T-Cell Development: Companies are increasingly investigating donor-derived and stem cell-derived T-cell platforms to reduce dependence on individualized manufacturing. Allogene Therapeutics' ALLO-329 program, for example, uses an off-the-shelf allogeneic CAR-T approach for autoimmune diseases. Research is also examining dual-target receptors, armored CAR-T cells, and gene-edited platforms to address antigen escape and limited T-cell activity within solid tumors. These programs represent potential changes in treatment accessibility and manufacturing, although most remain under clinical investigation. Market Outlook: The Novel T-Cell Immunotherapy Market is supported by established CAR-T treatment activity and expanding regulatory applications for TIL, TCR-T, and Treg-based therapies. Solid tumors and autoimmune diseases provide additional development opportunities, while allogeneic manufacturing and next-generation cell engineering could change treatment delivery. However, patient eligibility, manufacturing constraints, treatment-related toxicities, and competition from bispecific antibodies will influence the pace of adoption. The industry's commercial expansion through 2032 will depend on converting clinical progress into approved treatments and accessible patient-care pathways. Which Therapy Types and Cell Sources Account for Novel T-Cell Immunotherapy Market Revenue? Therapy Type Segmentation CAR-T Cell Therapy — Largest Therapy Category CAR-T accounts for an estimated 96.1% of 2025 market revenue, or USD 6.10 billion, with a projected value of USD 16.40 billion in 2032. The commercially important shift is toward treating patients earlier rather than relying solely on heavily pretreated populations. In the FDA's December 2025 marginal zone lymphoma decision, 95.5% of 66 infused patients responded and 62.1% achieved a complete response. These treatment outcomes strengthen the case for expanding approved indications, although referral rates and competing treatments determine actual utilization. Source: U.S. FDA. Tumor-Infiltrating Lymphocyte (TIL) Therapy — Expanding Solid Tumor Category TIL therapy accounts for an estimated 3.5% share, equivalent to USD 220 million in 2025, and is projected to reach USD 1.70 billion by 2032. Expansion beyond later-line melanoma is being tested in a 670-participant Phase III study comparing lifileucel plus pembrolizumab against pembrolizumab in previously untreated advanced melanoma. The trial has an estimated primary completion in 2028; therefore, first-line treatment remains a forecast opportunity, not an established indication. An approval would expand TIL use into a larger treatment population, but requires evidence that the added treatment burden produces meaningful clinical benefit. Source: ClinicalTrials.gov, NCT05727904. TCR-Engineered T-Cell Therapy — Early Commercial Development TCR-T represents an estimated 0.5% share, or approximately USD 30 million in 2025, with a 2032 opportunity of USD 900 million. Its current commercial base is restricted by tumor-antigen expression and compatible HLA types, making diagnostic eligibility central to uptake. The FDA expanded Tecelra's eligible age group to patients 12 years and older in June 2026, but retained the requirement for qualifying synovial sarcoma and pretreatment criteria. TCR-T will remain a specialized market unless additional antigen-defined solid-tumor populations become treatable. Source: FDA product information. Regulatory T-Cell Therapy — Newly Established Commercial Category Regulatory T-cell-based treatments contributed no separately identified material revenue in the 2025 model; the 2032 scenario allocates USD 350 million to the category. The 2026 FDA approval of Tregzi creates a defined transplantation market rather than a broad autoimmune Treg market. Importantly, the product contains several donor-derived cell populations and cannot be used as evidence that standalone CAR-Treg therapies have been approved. Commercial uptake will be measured by eligible matched-donor transplant procedures and transplant-program adoption, not the overall number of patients diagnosed with blood cancer. Source: U.S. FDA approved products. Virus-Specific T-Cell Therapy — Specialized Transplant-Related Application Virus-specific T-cell therapy serves a small, identifiable population with virus-associated complications after organ or stem cell transplantation. The European Medicines Agency authorized Ebvallo on December 16, 2022, for qualifying Epstein–Barr virus-positive post-transplant lymphoproliferative disease, under exceptional circumstances because the condition is rare. Its authorization demonstrates a commercial pathway outside oncology-directed CAR-T, but the narrow patient group and jurisdiction-specific authorization limit addressable demand. Expansion depends on additional transplant-virus indications and broader reimbursement decisions. Source: European Medicines Agency. Other Emerging T-Cell Therapies — Investigational Platforms Gamma-delta T cells and other engineered T-cell designs remain development-led categories rather than established contributors to product revenue. For example, an early study of CD19-directed gamma-delta CAR-T in relapsed or refractory non-Hodgkin lymphoma plans approximately 30 participants. Recruitment targets are not treated-patient totals and cannot support present commercial shares. The segment warrants a separate pipeline assessment, with revenue included only after an applicable approval and product launch. Source: ClinicalTrials.gov. Cell Source Segmentation Autologous T-Cell Therapy — Largest Established Cell Source Autologous treatment dominates commercial cellular oncology because leading approved CAR-T, TCR-T, and TIL products are manufactured from each patient's collected cells. The EBMT's 2024 activity study recorded 6,037 autologous first CAR-T infusions; these represented 99.3% of the reported first CAR-T procedures. This concentration confirms the current manufacturing model, but each patient requires a separate collection-and-production pathway. Wider adoption will depend on reducing treatment delays without compromising product release standards. Source: EBMT activity study, published 2026. Allogeneic T-Cell Therapy — Emerging Off-the-Shelf Category Allogeneic treatments could reduce individualized production requirements, but clinical evidence remains much narrower than for autologous CAR-T. The same EBMT activity study recorded 45 allogeneic first CAR-T recipients in 2024, down from 84 in 2023. This decline shows why clinical acceptance should not be inferred from the number of companies developing donor-derived cells. An allogeneic product must demonstrate adequate persistence and outcomes before batch manufacturing translates into a commercial advantage. Source: EBMT activity study. Stem Cell-Derived T-Cell Platforms — Emerging Manufacturing Category Stem cell-derived T cells are an alternative starting material for standardized production, but most programs remain investigational. A developer's November 2026 update reported 17 active recruitment sites in its Phase II RECLAIM-LN study, with approximately 53 patients planned for treatment of refractory lupus nephritis using a banked-cell CAR-T product. These details show an emerging outpatient development pathway rather than commercial penetration. Stem-cell derivation should remain an attribute within the allogeneic platform analysis to prevent double-counting. Source: Fate Therapeutics, November 2026. How Are Hematological Malignancies, Solid Tumors and Emerging Immune Disorders Influencing Market Revenue? Application Segmentation Hematological Malignancies — Largest Application Hematological malignancies remain the largest application and are projected to reach USD 14.42 billion in 2032, largely through approved CD19- and BCMA-directed treatments. Demand is not distributed evenly across diagnoses: the 2024 EBMT activity study recorded 3,215 diffuse large B-cell lymphoma procedures, compared with 1,102 multiple myeloma procedures. Multiple myeloma activity had risen from 736 the previous year, indicating a rapidly developing treatment group within the established blood-cancer market. The mix of eligible diagnoses and line-of-therapy approvals will have a greater effect on revenue than the overall cancer burden. Source: EBMT study. Solid Tumors — Major Emerging Application Solid tumors account for an estimated 3.9% share, equivalent to USD 250 million in 2025, with a projected 2032 value of USD 3.48 billion. In October 2026, a Phase II investigation of lifileucel in previously treated nonsquamous metastatic lung cancer reported 17 responses among 69 treated patients (24.6%). A retrospectively defined biomarker-enriched subgroup showed 13 responses among 22 patients, although this finding requires prospective confirmation. These data make patient selection central to future solid-tumor revenues, rather than assuming that all lung-cancer patients are candidates. Source: Iovance regulatory filing, October 2026. Autoimmune Diseases — Emerging Clinical Application Autoimmune disease treatment had no material approved-product sales in the 2025 model, and the forecast allocates approximately USD 1.20 billion in 2032 subject to new approvals. The EBMT documented 60 CAR-T procedures for autoimmune diseases in 2024 versus 36 in 2023, with systemic lupus erythematosus representing 35% of that activity. These are reported procedures, not an approved-product commercial population. The increase supports clinical interest, but revenue forecasts should depend on controlled-trial outcomes and evidence that treatment offers a meaningful alternative to ongoing immunosuppression. Source: EBMT study. Transplantation and Immune Regulation — Specialized Application Transplantation and immune regulation are to generate USD 300 million in 2032, following the introduction of an approved donor-derived Treg-based transplantation treatment. The EBMT reported 21,023 allogeneic hematopoietic cell transplants in 2024 across its participating centers. This establishes the broader service pathway, but most transplant recipients are not automatically eligible for the approved Treg-based product. Market adoption should be assessed against matched-donor transplants meeting the product's specified criteria, rather than all transplantation activity. Source: EBMT activity study. Infectious and Virus-Associated Diseases — Niche Application Infectious and virus-associated conditions are valued at USD 100 million in 2032, reflecting a specialized rather than mass-market treatment category. The EMA's Ebvallo approval specifically covers EBV-positive post-transplant lymphoproliferative disease after inadequate response to prior treatment; it is not an approval for ordinary EBV infections. This narrow clinical definition concentrates demand within transplant and hematology referral networks. Additional viral indications require separate efficacy evidence and regulatory review. Source: EMA authorization. Which Treatment Settings Account for Novel T-Cell Immunotherapy Demand? End-User Segmentation Hospitals — Largest Commercial Treatment Setting Hospitals capture most commercial T-cell therapy administration because they can deliver preparatory treatment, infusions, and emergency management of treatment-related complications. The FDA's 2025 removal of specified CAR-T REMS requirements reduced a formal certification burden, but did not remove safety monitoring from product labeling. The relevant market indicator is therefore the number of hospitals actually treating patients under product-specific protocols, not the number of hospitals offering oncology services. This gives established cellular-therapy hospitals a clear advantage in converting referrals into completed treatment. Source: FDA REMS decision. Specialized Cancer and Cell Therapy Centers — Expanding Treatment Setting Dedicated centers can shorten the distance between referral, cell collection and infusion for eligible cancer patients. A November 2026 manufacturer update reported 90 authorized U.S. treatment centers for its adult B-ALL CAR-T product, demonstrating the scale of a single-product delivery network. Authorization is not the same as active patient throughput, so commercial projections require center-level infusion counts and conversion of referred patients into treated patients. Source: Autolus corporate results. Academic Medical Centers — Clinical Development and Specialized Treatment Academic medical centers remain important for trials requiring uncommon tumor biomarkers or specialized cellular manufacturing arrangements. For example, early engineered T-cell studies in KRAS-mutated gastrointestinal tumors require molecular screening before recruitment, making academic molecular-oncology services directly relevant to eligible enrollment. Academic participation may establish future referral channels, but trial procedures and sponsor funding do not constitute approved-product revenue. Source: ClinicalTrials.gov. Transplantation Centers — Specialized Regulatory T-Cell Treatment Transplantation centers provide the commercial setting for donor-derived regulatory T-cell products and selected virus-specific therapies. Their clinical activity depends on donor matching, conditioning, graft preparation and post-transplant monitoring. The EMA's authorization of a virus-specific treatment under exceptional circumstances demonstrates that some products serve rare complications rather than routine transplant recipients. Consequently, this end-user segment should be sized using qualifying transplant episodes and post-transplant complications, not all admissions to transplant departments. Source: EMA product authorization. Which Countries Have the Strongest Commercial Positions in the Novel T-Cell Immunotherapy Market? United States — Largest Revenue-Contributing Country The United States accounts for an estimated 63.0% of global revenue, or USD 4.00 billion in 2025, and is projected to reach USD 10.20 billion by 2032. The country's largest-product concentration is illustrated by USD 1.492 billion in 2025 U.S. sales for Carvykti, compared with USD 869 million in 2024. This increase reflects strong uptake in an approved multiple myeloma indication, but should not be extrapolated to every CAR-T brand. The U.S. forecast is primarily sensitive to treatment-line eligibility, product competition and access to qualified infusion centers. Source: Johnson & Johnson 2025 results. Germany — Leading European CAR-T Treatment Market Germany represents an estimated 6.6% share, or USD 420 million in 2025, and is forecast at USD 1.45 billion in 2032. Its 2024 CAR-T treatment rate of 172.4 per 10 million residents was among the highest reported European rates, according to the EBMT. This measure is a stronger access indicator than simply counting regulatory approvals, because it adjusts for population size. Germany's future revenue will depend on treatment penetration within eligible lymphoma and myeloma populations and on manufacturer net prices. Source: EBMT activity study. France — Established Lymphoma and Cellular Therapy Market France accounts for an estimated 5.4% share, or USD 340 million in 2025, with 2032 value of USD 1.15 billion. In the 2024 EBMT survey, French centers reported 1,092 autologous CAR-T recipients. The national treatment base is therefore supported by administered therapy rather than pipeline announcements alone. Expansion into additional reimbursed lymphoma indications could increase treatment numbers, although patient eligibility and hospital capacity will govern actual revenues. Source: EBMT activity study. Japan — Established Commercial Market for Hematological Treatments Japan accounts for an estimated 4.7% share, equivalent to USD 300 million in 2025, and is projected to reach USD 1.05 billion by 2032. Japan's Pharmaceuticals and Medical Devices Agency identifies five authorized CAR-T brands in a 2025 safety review: Yescarta, Abecma, Carvykti, Kymriah and Breyanzi. The regulator's March 2025 review also required updated precautions for T-cell malignancies, showing that Japan's commercial market operates within an established product-surveillance system. National product-level revenue and infusion counts remain necessary to validate the forecast share. Source: Japan PMDA, March 2025. United Kingdom — Commercial Expansion Through NHS Treatment Access The United Kingdom represents an estimated 3.9% share, or USD 250 million in 2025, and is projected to reach USD 950 million by 2032. The UK recorded 548 autologous CAR-T recipients in the 2024 EBMT survey. Its 2026 access environment also includes routine NHS commissioning of Aucatzyl for eligible adults with B-cell acute lymphoblastic leukemia, making reimbursement an observable driver of treatment adoption. Future market development depends on whether commissioning decisions are matched by referrals and available infusion capacity. Sources: EBMT; Autolus update. Italy — Established CAR-T Treatment Network Italy accounts for an estimated 3.6% share, or USD 230 million in 2025, with a 2032 forecast of USD 850 million. The EBMT identified 678 autologous CAR-T recipients in Italy during 2024, establishing a substantial infusion base. This utilization figure should be assessed alongside regional distribution of treatment facilities: demand can exist nationally without equal access in every region. Commercial expansion depends on locally reimbursed indications and treatment completion, not hospital designation alone. Source: EBMT activity study. Spain — Significant Clinical Treatment Activity Spain represents an estimated 2.8% share, equivalent to USD 180 million in 2025, and is forecast at USD 700 million in 2032. Its 2024 CAR-T treatment rate was 156.9 per 10 million people, demonstrating substantial utilization relative to population size. This relatively high rate contrasts with its lower revenue share, emphasizing uncertainty around net product pricing and therapy mix. The forecast needs country-specific procurement and reimbursement data before the estimated revenue ranking can be considered independently verified. Source: EBMT activity study. China — Domestic CAR-T Commercialization and Product Development China accounts for an estimated 2.4% share, or USD 150 million in 2025, with USD 1.50 billion opportunity in 2032. A domestic manufacturer reported RMB 218.96 million in 2025 Carteyva product sales, a 38.4% year-on-year increase. This provides evidence of real commercial adoption but represents only one product, not the national market. Additional locally approved products and hospital treatment volumes must be incorporated before Chinese revenues can be estimated with confidence. Source: JW Therapeutics 2025 annual results. Canada — Provincial Funding Determines Treatment Access Canada represents an estimated 1.9% share, equivalent to USD 120 million in 2025, and is projected to reach USD 550 million in 2032. Unlike the U.S. market, the availability of approved CAR-T medicines across Canada must be converted into provincial funding and designated-center access. The key commercial variable is whether eligible patients can obtain a funded referral to a center authorized for their specific product. Because national therapy-specific manufacturer sales are not publicly consolidated, the country share remains provisional and requires provincial reimbursement and utilization records for confirmation. Which Companies Are Competing in the Global Novel T-Cell Immunotherapy Market? Gilead Sciences / Kite Pharma — Established CD19-Directed CAR-T Portfolio Kite's Yescarta and Tecartus give Gilead exposure to several B-cell lymphoma and leukemia indications. In its 2025 financial disclosure, Yescarta revenue declined 5% and Tecartus revenue declined 15% year-on-year. These declines show that an established approved-product portfolio does not guarantee growth as treatment sequencing and competing options change. The key competitive question is whether the products can defend their position in increasingly contested eligible patient groups. Source: Gilead 2025 results. Bristol Myers Squibb — CAR-T Products Across Lymphoma and Multiple Myeloma The company's CAR-T portfolio covers both CD19-directed lymphoma treatment and BCMA-directed myeloma care. Its 2025 annual report recorded 82% year-on-year growth for Breyanzi compared with 5% for Abecma. This divergence highlights indication-specific competition and adoption rather than a uniform CAR-T market trajectory. The commercial outlook should therefore be assessed separately for lymphoma and multiple myeloma. Source: BMS 2025 annual filing. Novartis — Established CAR-T Product Facing Competition Novartis commercializes Kymriah for selected B-cell malignancies. In its 2025 annual report, Kymriah's worldwide net sales fell 14% from 2024, indicating pressure on an earlier approved cellular treatment. The decline is a reminder that additional market entrants can redistribute treatment volumes even while CAR-T utilization expands overall. Sustaining product revenue depends on differentiated clinical positioning and prescribing access. Source: Novartis 2025 annual report. Autolus Therapeutics — Adult B-ALL Commercialization and Pipeline Expansion Autolus is developing its adult B-ALL CAR-T franchise alongside new patient groups. The company's 2026 update reported a third-quarter Aucatzyl product revenue of USD 41.2 million, up 95% year-on-year, indicating continued uptake after its initial commercialization. The durability of growth will depend on completed infusions, center throughput and progress in pediatric and autoimmune programs. Source: Autolus company updates. Iovance Biotherapeutics — TIL Treatment and Lung Cancer Pipeline Iovance is investigating whether an existing melanoma TIL platform can support a second solid-tumor indication. Its October 2026 lung-cancer update identified KRAS wild-type patients with a 43.3% response rate versus 11.4% among KRAS-mutant patients in an exploratory comparison. The difference supports prospective biomarker-based study design but does not establish an approved lung cancer therapy. The value of Iovance's pipeline will depend on confirming a treatable subgroup and obtaining regulatory authorization. Source: Iovance October 2026. Adaptimmune Therapeutics — Targeted TCR-T Treatment The Tecelra TCR-T franchise is commercially differentiated by its requirement for both tumor MAGE-A4 expression and an eligible HLA type. This creates a narrower prescribable population than a cancer diagnosis alone would suggest. An important commercialization measure is the share of referred synovial sarcoma patients who complete both qualifying tests and proceed to cell collection. The success of this model depends on biomarker identification and access to specialist cellular therapy centers. Source: FDA Tecelra record. Orca Bio — Treg-Based Transplantation Product Orca Bio's competitive position is built around an approved donor-derived graft product for matched-donor transplantation. Its clinical evidence supports the reduction of chronic graft-versus-host disease risk without treating the product as a conventional cancer-directed CAR-T therapy. Commercial demand will be determined by transplant-center decisions for eligible procedures, rather than broad oncology prescribing. Source: FDA cellular therapy approvals. Allogene Therapeutics — Allogeneic CAR-T Clinical Development Allogene is pursuing an off-the-shelf platform across cancer and autoimmune indications. Its November 2026 program update stated that ALPHA3 trial enrollment is expected to finish by year-end 2027, with a clinical update targeted for mid-2027. This timeline makes the large B-cell lymphoma program a future competitive entry rather than a current commercial revenue contributor. Its development risk centers on reproducing effective cellular therapy outcomes using donor-derived material. Source: Allogene November 2026 update. Fate Therapeutics — Stem Cell-Derived T-Cell Platform Fate's banked-cell FT819 program provides a test of whether stem cell-derived CAR-T therapy can be delivered outside conventional inpatient pathways. In November 2026, the company reported 12 of 36 autoimmune trial patients (33%) received outpatient treatment, including eight discharged on the infusion day. These preliminary outcomes support research into less resource-intensive administration but do not establish approved outpatient indications. Source: Fate Therapeutics, November 10, 2026. JW Therapeutics — Domestic CAR-T Platform in China JW's Carteyva business provides an example of domestically developed commercial CAR-T treatment, rather than solely licensed imported products. Its future position will depend on expansion into additional approved indications, uptake at qualified Chinese hospitals, and competition from other domestic cell therapy manufacturers. A China-specific market assessment must therefore track national approvals and treating-center volumes separately from company-reported revenue. Source: JW Therapeutics corporate disclosures. Pierre Fabre — European Virus-Specific T-Cell Treatment Pierre Fabre is the EMA-listed marketing authorization holder for Ebvallo. The EMA updated its public product information on October 2, 2026, while the medicine remained authorized for a narrow post-transplant indication. The product's market is therefore governed by referral from transplant specialists and the small number of eligible patients, rather than conventional oncology market size. Source: EMA product record. What Will Shape Revenue Opportunities in the Novel T-Cell Immunotherapy Market Through 2032? The commercial foundation of the Novel T-Cell Immunotherapy Market remains concentrated in CAR-T treatments for hematological malignancies. Additional FDA-approved indications are expanding the use of established products, while Amtagvi and Tecelra have established commercial treatment pathways for selected solid tumors. The approval of Tregzi has also introduced a separate transplantation-related application. The strongest emerging opportunities are associated with allogeneic CAR-T, autoimmune disease applications, armored cell designs, and in vivo T-cell engineering. These technologies could change how therapeutic cells are manufactured and delivered, but their contribution will depend on clinical validation and regulatory approvals. For manufacturers, the principal commercial constraints remain patient referral, manufacturing capacity, treatment-related safety, and competition from bispecific antibodies. The ability to address these limitations while demonstrating durable clinical outcomes will determine how effectively clinical development translates into wider treatment adoption through 2032. Novel T-Cell Immunotherapy Market Report Coverage Table Report Attribute Details Forecast Period 2026 – 2032 Market Size Value in 2025 USD 6.35 Billion Revenue Forecast in 2032 USD 19.50 Billion Overall Growth Rate CAGR of 17.1% (2026 – 2032) Base Year for Estimation 2025 Historical Data 2019 – 2024 Unit USD Million/Billion, CAGR (2026 – 2032) Segmentation By Therapy Type, By Cell Source, By Application, By End User, By Geography By Therapy Type CAR-T Cell Therapy, Tumor-Infiltrating Lymphocyte (TIL) Therapy, TCR-Engineered T-Cell Therapy, Regulatory T-Cell Therapy, Virus-Specific T-Cell Therapy, Other T-Cell Therapies By Cell Source Autologous T-Cell Therapy, Allogeneic T-Cell Therapy, Stem Cell-Derived T-Cell Therapy By Application Hematological Malignancies, Solid Tumors, Autoimmune Diseases, Transplantation and Immune Regulation, Infectious and Virus-Associated Diseases By End User Hospitals, Specialized Cancer and Cell Therapy Centers, Academic Medical Centers, Transplantation Centers By Region North America, Europe, Asia-Pacific, Latin America, Middle East & Africa Country Scope U.S., Canada, UK, Germany, France, Italy, China, Japan, South Korea, India, Brazil, Mexico, Saudi Arabia, UAE, South Africa Market Drivers Established CAR-T treatment activity, expansion of approved indications, TIL and TCR-T therapies for selected solid tumors, clinical development of allogeneic and regulatory T-cell therapies Customization Option Available upon request Frequently Asked Question About This Report Q1. What is keeping demand strong in the novel T-cell immunotherapy market? A1. Expanding CAR-T treatment indications and established use in blood cancers are supporting demand. The European Society for Blood and Marrow Transplantation recorded 4,757 CAR-T procedures in its registry during 2025. The FDA also lists seven approved CAR-T products targeting CD19 and BCMA, demonstrating an established commercial treatment base. Q2. How are solid tumor applications widening commercial opportunities in the industry? A2. FDA approvals of TIL and TCR-T treatments are extending cellular immunotherapy beyond hematological cancers. Amtagvi demonstrated an objective response rate of 31.5% in previously treated advanced melanoma, while Tecelra achieved a 43.2% response rate in eligible synovial sarcoma patients. These developments are creating additional opportunities in specialized solid tumor treatment. Q3. Which treatment segment is expected to generate the largest revenue in the market? A3. CAR-T cell therapy dominates with an estimated 96.1% revenue share, equivalent to USD 6.10 billion in 2025. Its leadership reflects approved treatments across leukemia, lymphoma, and multiple myeloma. Expansion into earlier treatment lines and additional approved indications is supporting continued commercial demand. Q4. What impact are regulatory changes having on treatment adoption in the industry? A4. The FDA eliminated specified REMS requirements for approved autologous CD19- and BCMA-directed CAR-T therapies in June 2025. Removing special hospital certification requirements can make treatment more accessible to patients in underserved and rural areas. However, product-specific safety monitoring and clinical precautions remain important. Q5. Which regions are expected to create the strongest growth opportunities in the market? A5. Asia-Pacific is projected to record the fastest regional growth at a CAGR of 25% through 2032. China is expected to grow at 27%, supported by domestic biotechnology development and clinical research. North America remains the largest regional market with an estimated 48% revenue share in 2025. Q6. Why are developers investing in allogeneic cell therapy platforms in the industry? A6. Allogeneic platforms offer the potential to reduce dependence on individualized cell collection and manufacturing. Allogene Therapeutics is evaluating ALLO-329 for autoimmune diseases, with preliminary Phase I results involving 18 patients across three indications reported in November 2026. These approaches remain investigational but could create new treatment opportunities beyond oncology. Q7. What commercial barriers could slow expansion of the market? A7. Manufacturing capacity, patient eligibility, treatment-related toxicities, and competition from bispecific antibodies remain important challenges. Cellular therapies also require specialized treatment centers and structured patient monitoring. Manufacturers must demonstrate durable clinical benefits while improving treatment accessibility and managing administration costs. Sources: U.S. FDA – Approved Breyanzi for Adults With Relapsed or Refractory Marginal Zone Lymphoma After at Least Two Prior Treatment Lines on December 4, 2025 FDA – Breyanzi Indication Expansion: Marginal Zone Lymphoma Approval and Clinical Evidence U.S. FDA – Approved Orca Bio’s Tregzi on June 30, 2026, for Eligible Adults Undergoing Matched-Donor Hematopoietic Stem Cell Transplantation, Supported by the 187-Patient Precision-T Trial FDA – Tregzi: Regulatory T-Cell-Based Transplantation Therapy Approval U.S. FDA – June 17, 2026, Tecelra Approval Includes Patients Aged 12 Years and Older With Previously Treated Synovial Sarcoma Meeting Specified HLA and MAGE-A4 Requirements FDA – Tecelra: Updated Patient Eligibility and June 2026 Approval Documents U.S. FDA – June 2025 REMS Elimination Removed Special Hospital Certification and Immediate On-Site Tocilizumab Requirements Under the Programs for Six Listed Autologous CAR-T Products FDA – CAR-T REMS Elimination, Updated Monitoring Requirements, and Continuing Safety Oversight Allogene Therapeutics – November 9, 2026, Update Reported Preliminary ALLO-329 Phase I Findings From 18 Patients With Systemic Sclerosis, Inflammatory Myopathies, or Systemic Lupus Erythematosus Allogene – RESOLUTION Study: Investigational Allogeneic CAR-T Development in Autoimmune Disease Fate Therapeutics – November 10, 2026, Update Reported That 12 of 36 FT819 Trial Patients Received Outpatient Administration, Including Eight Discharged on Infusion Day Fate Therapeutics – FT819: Updated Autoimmune Trial Results and Outpatient Administration Experience Autolus Therapeutics – Reported AUCATZYL Net Product Revenue of USD 41.2 Million for Q3 2026, Representing 95% Year-Over-Year Growth, in Its November 10 Update Autolus – Third-Quarter 2026 Results: AUCATZYL Commercial Adoption and Development Programs Iovance Biotherapeutics – October 29, 2026, Disclosure Reported a 24.6% Response Rate Among 69 Patients in the Investigational Lifileucel Lung Cancer Study SEC – Iovance Clinical Update: IOV-LUN-202 Results and Biomarker-Based TIL Development Table of Contents - Global Novel T-Cell Immunotherapy Market Report (2026–2032) Executive Summary Market Overview Market Attractiveness by Therapy Type, Cell Source, Application, End User, and Region Strategic Insights from Key Executives (CXO Perspective) Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Summary of Market Segmentation by Therapy Type, Cell Source, Application, End User, and Region Market Share Analysis Leading Players by Revenue and Market Share Market Share Analysis by Therapy Type, Cell Source, Application, and End User Investment Opportunities in the Novel T-Cell Immunotherapy Market Key Developments and Innovations Mergers, Acquisitions, and Strategic Partnerships High-Growth Segments for Investment Opportunities in CAR-T Cell Therapy, TIL Therapy, TCR-Engineered T-Cell Therapy, Regulatory T-Cell Therapy, Virus-Specific T-Cell Therapy, Allogeneic CAR-T Platforms, and Stem Cell-Derived T-Cell Platforms Emerging Opportunities in Solid Tumors, Autoimmune Diseases, and Transplantation-Related Applications Market Introduction Definition and Scope of the Study Market Structure and Key Findings Overview of Top Investment Pockets Strategic Importance of Novel T-Cell Immunotherapy in Hematological Malignancies, Solid Tumors, Autoimmune Diseases, Transplantation, and Infectious Diseases Research Methodology Research Process Overview Primary and Secondary Research Approaches Market Size Estimation and Forecasting Techniques Data Triangulation and Segment-Level Forecasting Approach Assessment of Treatment Volumes, Approved Products, Clinical Pipeline Activity, and Commercial Adoption Market Dynamics Key Market Drivers Challenges and Restraints Impacting Growth Emerging Opportunities for Stakeholders Impact of Regulatory Approvals and Treatment Accessibility Role of CAR-T Treatment Adoption and Expanding Hematological Malignancy Indications in Market Expansion Impact of TIL and TCR-T Approvals on Solid Tumor Treatment Development Allogeneic Manufacturing, Stem Cell-Derived Platforms, and Next-Generation T-Cell Engineering Trends Patient Eligibility, Manufacturing Constraints, Treatment-Related Toxicities, and Competition from Bispecific Antibodies Global Novel T-Cell Immunotherapy Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Therapy Type: CAR-T Cell Therapy Tumor-Infiltrating Lymphocyte (TIL) Therapy TCR-Engineered T-Cell Therapy Regulatory T-Cell Therapy Virus-Specific T-Cell Therapy Other T-Cell Therapies Market Analysis by Cell Source: Autologous T-Cell Therapy Allogeneic T-Cell Therapy Stem Cell-Derived T-Cell Therapy Market Analysis by Application: Hematological Malignancies Solid Tumors Autoimmune Diseases Transplantation and Immune Regulation Infectious and Virus-Associated Diseases Market Analysis by End User: Hospitals Specialized Cancer and Cell Therapy Centers Academic Medical Centers Transplantation Centers Market Analysis by Region: North America Europe Asia-Pacific Latin America Middle East & Africa Regional Market Analysis North America Novel T-Cell Immunotherapy Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Therapy Type, Cell Source, Application, and End User Country-Level Breakdown: United States Canada Europe Novel T-Cell Immunotherapy Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Therapy Type, Cell Source, Application, and End User Country-Level Breakdown: Germany France United Kingdom Italy Spain Rest of Europe Asia-Pacific Novel T-Cell Immunotherapy Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Therapy Type, Cell Source, Application, and End User Country-Level Breakdown: China Japan South Korea India Rest of Asia-Pacific Latin America Novel T-Cell Immunotherapy Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Therapy Type, Cell Source, Application, and End User Country-Level Breakdown: Brazil Mexico Rest of Latin America Middle East & Africa Novel T-Cell Immunotherapy Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Therapy Type, Cell Source, Application, and End User Country-Level Breakdown: Saudi Arabia United Arab Emirates South Africa Rest of Middle East & Africa Competitive Intelligence and Benchmarking Leading Key Players: Gilead Sciences / Kite Pharma Bristol Myers Squibb Novartis Autolus Therapeutics Iovance Biotherapeutics Adaptimmune Therapeutics Orca Bio Allogene Therapeutics Fate Therapeutics JW Therapeutics Pierre Fabre Legend Biotech Atara Biotherapeutics Immatics Arcellx Competitive Landscape and Strategic Insights Benchmarking Based on Approved Therapy Portfolios, Treatment Volumes, Clinical Outcomes, Manufacturing Platforms, and Regional Presence CAR-T Product Portfolio and Commercial Positioning TIL and TCR-T Solid Tumor Pipeline Competitiveness Allogeneic CAR-T and Stem Cell-Derived Platform Benchmarking Regulatory T-Cell and Transplantation Therapy Positioning Virus-Specific T-Cell Therapy and Infectious Disease Application Analysis Appendix Abbreviations and Terminologies Used in the Report References and Sources Historical Data Coverage (2019–2024) Base Year Definitions and Assumptions (2025) Forecast Assumptions and Market Scope (2026–2032) List of Tables Market Size by Therapy Type, Cell Source, Application, End User, and Region (2026–2032) Regional Market Breakdown by Therapy Type, Cell Source, Application, and End User (2026–2032) Country-Level Market Assessment Across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa Competitive Benchmarking of Leading Novel T-Cell Immunotherapy Companies Approved CAR-T, TIL, TCR-T, Regulatory T-Cell, and Virus-Specific T-Cell Therapy Portfolios Clinical Pipeline and Development Status of Allogeneic and Stem Cell-Derived T-Cell Platforms Treatment Volume and Cell Source Analysis (2019–2024) Market Development and Regulatory Milestones (2025–2026) List of Figures Market Drivers, Challenges, Opportunities, and Restraints Regional Market Snapshot Competitive Landscape by Market Share Growth Strategies Adopted by Key Players Market Share by Therapy Type, Cell Source, Application, and End User (2025 vs. 2032) Global Novel T-Cell Immunotherapy Ecosystem and Value Chain Analysis CAR-T Treatment Adoption and Solid Tumor Therapy Expansion Autologous, Allogeneic, and Stem Cell-Derived T-Cell Platform Comparison Clinical and Commercial Development Trends in Autoimmune and Transplantation Applications (2025–2026)